Eliminates the Intelligence Community veto of declassification decisions made by the Interagency Security Classification Appeals Panel (ISCAP) regarding intelligence sources and methods.
With its vote, the advisory panel is suggesting that hydrocodone be moved from its current classification as a Schedule III drug -- a drug with moderate abuse potential -- to a more restrictive Schedule II classification.